{
    "nct_id": "NCT06173518",
    "official_title": "A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients With CD19-Positive Relapsed/ Refractory (r/r) B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL)",
    "inclusion_criteria": "INCLUSION CRITERIA:\n\n* Male or female patients < 18 years old at screening\n* Patients with ≥ 6 kg body weight at screening\n\nB ALL Cohort: r/r CD19-positive B ALL defined as:\n\n* Primary refractory disease defined as:\n\n  1. National Cancer Institute (NCI) high risk or Children's Oncology Group (COG) high risk patients with MRD ≥ 0.1% EOI (end of induction) or >0.01% at EOC (end of consolidation) as assessed by flow cytometry.\n  2. COG intermediate risk cytogenetics with MRD ≥ 1% EOI as assessed by flow cytometry.\n  3. COG good risk cytogenetics with ≥ 5% disease EOI as assessed by flow cytometry\n  4. Down syndrome with MRD ≥ 0.01% EOC as assessed by flow cytometry.\n  5. High risk infant ALL (MRD-positive disease as assessed by flow cytometry post induction and blinatumomab)\n* Children's Oncology Group (COG) very high risk first relapse if first remission ≤18 months.\n* Relapsed or refractory disease after two or more lines of systemic therapy.\n* Relapsed or refractory disease after allogeneic transplant provided AUTO1 infusion occurs ≥3 months after stem cell transplant..\n* Any of the above with Philadelphia chromosome positive disease (Ph+ ALL) where patient is intolerant to or has failed at least one tyrosine kinase inhibitor (TKI) or if TKI therapy is contraindicated\n\nB NHL Cohort: r/r CD19-positive aggressive mature B NHL defined as:\n\n* Relapsed after one or more prior therapies (can include allogeneic and autologous hematopoietic stem cell transplant)\n* Primary refractory (have not achieved a CR or PR after the first line of therapy) with measurable, disease by radiological criteria at screening including the B NHL subtypes: (i) diffuse large B-cell lymphoma (DLBCL), (ii) Burkitt's lymphoma, (iii) primary mediastinal large B-cell lymphoma (PMBCL) and (iv) high-grade B-cell lymphoma (not otherwise specified)\n* Karnofsky (age ≥ 10 years) or Lansky (age < 10 year) performance status score ≥ 50%.\n* In patients with B ALL, local documentation of CD19 expression on leukemic blasts in the BM, peripheral blood, or cerebrospinal fluid (CSF) or biopsy done no more than 30 days prior to consent\n* Adequate renal, hepatic, pulmonary, and cardiac function\n\nEXCLUSION CRITERIA:\n\n* Diagnosis of chronic myelogenous leukemia lymphoid in blast crisis\n* History or presence of clinically relevant central nervous system (CNS) pathology\n* Presence of CNS 3 disease or CNS 2 disease with neurological changes at screening\n* Presence of active or uncontrolled fungal, bacterial, viral, or other infection requiring systemic antimicrobials for management\n* Patients who had prior (< 3 months before AUTO 1 infusion) stem cell transplant\n* Prior CD19 targeted therapy other than blinatumomab\n* Patients who have experienced ≥ Grade 3 neurotoxicity following blinatumomab\nHealthy volunteers allowed\nMust have minimum age of 0 Years\nMust have maximum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}